| Symbol | PRQR |
|---|---|
| Name | PROQR THERAPEUTICS N.V. |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | ZERNIKEDREEF 9, LEIDEN, 2333 CK, Netherlands |
| Telephone | +31 881667000 |
| Fax | — |
| — | |
| Website | https://www.proqr.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001612940 |
| Description | ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Lebers congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. Additional info from NASDAQ: |
New Form F-3 - ProQR Therapeutics N.V. <b>Filed:</b> 2026-07-06 <b>AccNo:</b> 0001104659-26-080750 <b>Size:</b> 971 KB
Read moreNew Form SCHEDULE 13D/A - ProQR Therapeutics N.V. <b>Filed:</b> 2026-06-30 <b>AccNo:</b> 0001104659-26-079415 <b>Size:</b> 27 KB
Read moreProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
Read moreProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
Read moreDirector Hinsch Gylvin Lykke 🟢 acquired 14.5K shares (1 derivative) of ProQR Therapeutics N.V. (PRQR) at $1.42 Transaction Date: Jun 02, 2026 | Filing ID: 070090
Read moreNew Form SCHEDULE 13D/A - ProQR Therapeutics N.V. <b>Filed:</b> 2026-06-03 <b>AccNo:</b> 0001104659-26-070195 <b>Size:</b> 43 KB
Read moreNew Form 3 - ProQR Therapeutics N.V. <b>Filed:</b> 2026-06-02 <b>AccNo:</b> 0001104659-26-069449 <b>Size:</b> 11 KB
Read moreProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05052554 | Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molec… | Phase1 | Fuchs Endothelial Corneal Dystrophy | Withdrawn | 2021-08-10 | 2022-04-12 | ClinicalTrials.gov |
| NCT04855045 | An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial … | Phase2 | Leber Congenital Amaurosis 10 | Unknown | 2021-03-23 | 2023-12-01 | ClinicalTrials.gov |
| NCT04123626 | A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Aut… | Phase1 | Autosomal Dominant Retinitis Pigmentosa | Active_Not_Recruiting | 2019-10-07 | 2022-06-07 | ClinicalTrials.gov |
| NCT03913143 | A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-… | Phase2 | Leber Congenital Amaurosis 10 | Active_Not_Recruiting | 2019-04-04 | 2023-03-01 | ClinicalTrials.gov |
| NCT03780257 | Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to… | Phase1 | Retinitis Pigmentosa | Completed | 2019-03-06 | 2021-10-14 | ClinicalTrials.gov |
| NCT02564354 | Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFT… | Phase1 | Cystic Fibrosis | Completed | 2015-09-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02532764 | Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients | Phase1 | Cystic Fibrosis | Completed | 2015-06-01 | 2017-09-14 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT02532764 |
| QR-010 | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT02532764 |
| QR-010 | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT02564354 |
| Sham | Other | Phase PHASE2 | Leber Congenital Amaurosis 10 | ACTIVE_NOT_RECRUITING | NCT03913143 |
| sepofarsen | Other | Phase PHASE2 | Leber Congenital Amaurosis 10 | ACTIVE_NOT_RECRUITING | NCT03913143 |
| sepofarsen | Other | Phase PHASE2 | Leber Congenital Amaurosis 10 | UNKNOWN | NCT04855045 |
| Sham-procedure (dose cohort 1&2 only) | Procedure | Phase PHASE1 | Retinitis Pigmentosa | COMPLETED | NCT03780257 |
| QR-421a | Other | Phase PHASE1 | Retinitis Pigmentosa | COMPLETED | NCT03780257 |
| Sham procedure | Procedure | Phase PHASE1 | Autosomal Dominant Retinitis Pigmentosa | ACTIVE_NOT_RECRUITING | NCT04123626 |
| QR-1123 | Other | Phase PHASE1 | Autosomal Dominant Retinitis Pigmentosa | ACTIVE_NOT_RECRUITING | NCT04123626 |
| QR-504a | Other | Phase PHASE1 | Fuchs Endothelial Corneal Dystrophy | WITHDRAWN | NCT05052554 |